Categories: NewsPharmaceutical

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Conference Call Details

Date and Time: Thursday, September 26, 2024, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 216512.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51231, and accessible on the Investors section of the Company’s website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until October 10, 2024, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 51231.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management

Digital health platform offers FDA-approved treatments when appropriate and personalized care plans through licensed providers.New…

14 hours ago

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June…

2 days ago

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

2 days ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

2 days ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

2 days ago